Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  SANOFI    SAN   FR0000120578

SANOFI (SAN)

2479
Real-time Quote. Real-time Tradegate - 10/20 04:04:05 pm
80.728 EUR   -0.64%
2h ago Actavis, Sanofi among bidders for Omega Pharma- Bloomberg
10h ago SANOFI : Results from Two Phase III Studies Added to U.S. Label of Genzyme&..
13h ago SANOFI : Restates Commitment to CSR in Africa
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.

MAIN FACTS:

- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at inti.landauro@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : SANOFI
Latest news on SANOFI
2h ago Actavis, Sanofi among bidders for Omega Pharma- Bloomberg
9h ago SANOFI : Premier Sponsor of DiabetesSisters 2014 Weekend for Women
10h ago SANOFI : Results from Two Phase III Studies Added to U.S. Label of Genzyme&rsquo..
13h ago SANOFI : Restates Commitment to CSR in Africa
19h ago SANOFI : : and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patient..
3d agoDJAmgen Files Patent Infringement Suit Over Cholesterol Drug
3d ago SANOFI : Pasteur and Immune Design Collaborate on a Vaccine to Treat Herpes Simp..
4d ago SANOFI : Pasteur and Immune Design Enter Broad Collaboration for the Development..
4d ago SANOFI : Unit starts phase 3 trial of rotavirus vaccine
4d ago SANOFI : French firm pledges commitment to local health sector
Advertisement
Chart
Duration : Period :
SANOFI Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF